1	Robust induction of B cell and T cell responses by a third dose of
2	inactivated SARS-CoV-2 vaccine
3	Yihao Liu <sup>1,2,3#</sup> , Qin Zeng <sup>4#</sup> , Caiguanxi Deng <sup>3#</sup> , Mengyuan Li <sup>4#</sup> , Liubing Li <sup>5#</sup> ,
4	Dayue Liu <sup>6#</sup> , Ming Liu <sup>3</sup> , Xinyuan Ruan <sup>4</sup> , Jie Mei <sup>2</sup> , Ruohui Mo <sup>2</sup> , Qian Zhou <sup>2</sup> , Min
5	Liu <sup>5</sup> , Sui Peng <sup>2,3</sup> , Ji Wang <sup>3*</sup> , Hui Zhang <sup>3,4*</sup> , Haipeng Xiao <sup>1*</sup>
6	
7	<sup>1</sup> Department of Endocrinology, The First Affiliated Hospital of Sun Yat-sen
8	University, Guangzhou 510080, People's Republic of China
9	<sup>2</sup> Clinical Trials Unit, The First Affiliated Hospital of Sun Yat-sen University,
10	Guangzhou 510080, People's Republic of China
11	<sup>3</sup> Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-sen
12	University, Guangzhou 510080, People's Republic of China
13	<sup>4</sup> Department of Rheumatology and Clinical Immunology, The First Affiliated
14	Hospital of Sun Yat-sen University, Guangzhou 510080, People's Republic of
15	China
16	<sup>5</sup> Department of Laboratory Medicine, The First Affiliated Hospital of Sun
17	Yat-sen University, Guangzhou 510080, People's Republic of China
18	<sup>6</sup> Department of Medical Affairs, The First Affiliated Hospital of Sun Yat-sen
19	University, Guangzhou 510080, People's Republic of China
20	
21	Running title: third dose of inactivated SARS-CoV-2 vaccine.

#These authors contributed equally to this work. 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 \*Co-correspondent authors
- 24 \*Lead contact:
- 25 Haipeng Xiao, MD, PhD
- 26 Professor of Medicine in Endocrinology
- 27 President of the First Affiliated Hospital of Sun Yat-sen University
- 58 ZhongShan Second Road, Guangzhou, 510080, P. R. China.
- 29 Tel: +86-136-0976-3571
- 30 E-mail: xiaohp@mail.sysu.edu.cn
- 31

# 32 Abstract:

SARS-CoV-2 inactivated vaccines have shown remarkable efficacy in clinical 33 trials, especially in reducing severe illness and casualty. However, the waning 34 of humoral immunity over time has raised concern over the durability of 35 immune memory following vaccination. Thus, we conducted a non-randomized 36 trial among the healthcare professionals (HCWs) to investigate the long-term 37 sustainability of SARS-CoV-2-specific B cells and T cells stimulated by 38 inactivated vaccines and the potential need for a third booster dose. Although 39 40 neutralizing antibodies elicited by the standard two-dose vaccination schedule dropped from a peak of 29.3 AU/ml to 8.8 AU/ml 5 months after the second 41 vaccination, spike-specific memory B and T cells were still detectable, forming 42 43 the basis for a quick recall response. As expected, the faded humoral immune response was vigorously elevated to 63.6 AU/ml by 7.2 folds 1 week after the 44 third dose along with abundant spike-specific circulating follicular helper T cells 45 in parallel. Meanwhile, spike-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells were also 46 robustly elevated by 5.9 and 2.7 folds respectively. Robust expansion of 47 memory pools by the third dose potentiated greater durability of protective 48 immune responses. Another key finding in this trial was that HCWs with low 49 serological response to 2 doses were not truly "non-responders" but fully 50 equipped with immune memory that could be quickly recalled by a third dose 51 52 even 5 months after the second vaccination. Collectively, these data provide insights into the generation of long-term immunological memory by the 53

- 54 inactivated vaccine, which could be rapidly recalled and further boosted by a
- 55 third dose.
- 56
- 57 Key words: SARS-CoV-2, inactivated vaccine, immunological memory,
- 58 SARS-CoV-2-specific memory B cells, SARS-CoV-2-specific memory T cells,
- 59 booster dose
- 60

# 61 Introduction

The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread across the globe currently<sup>1, 2</sup>. The pandemic has brought profound casualties of human lives and socioeconomic issues. The establishment of herd immunity by vaccination represents the most cost-effective strategy to prevent COVID-19. The rapid spreading of COVID-19 has urged the governments to authorize the emergent use of vaccines against SARS-CoV-2<sup>3-5</sup>.

69

The presence of neutralizing antibodies (NAbs) against SARS-CoV-2 is an 70 indicator of protective immunity after vaccination or infection<sup>6, 7</sup>. NAbs capable 71 72 of blocking the interaction between the spike protein and its receptor angiotensin converting enzyme 2 (ACE2) are particularly important for 73 protection from COVID-19<sup>8</sup>. Therefore, inducing potent NAbs and long-lasting 74 75 memory B cells are the primary goal of SARS-CoV-2 vaccines. Two doses of mRNA or inactivated vaccines are capable of inducing potent neutralizing 76 antibody responses <sup>9,3, 10</sup>. Our previous study further demonstrated that 77 inactivated vaccines elicited SARS-CoV-2 specific memory B cells<sup>11</sup>, which are 78 79 important for a rapid and robust recall of protective responses against viral infection. However, little is known how long can these immune responses 80 81 sustain. A rapid decline of neutralizing antibodies has been observed among infected healthcare workers (HCWs)<sup>12</sup>. Neutralizing antibodies also waned 82

overtime after the second dose of BNT162b2 or ChAdOx1<sup>13</sup>, indicating weakened protection for SARS-CoV-2 infection. In addition, the rapid emergence of novel SARS-CoV-2 variants of concern (VOCs) dampens the efficacy of SARS-CoV-2 vaccines, since vaccine-induced antibodies were less effective in neutralizing some emerging VOCs<sup>14</sup>. Moreover, cross-reactive antibodies against VOCs decayed even faster than antibodies against wild-type strain<sup>15</sup>.

90

91 Besides humoral immune responses, T cells also play a pivotal role in coordinating the adaptive immune responses and as effectors against viral 92 infection. In some cases, patients with inherited or treatment-induced B cell 93 deficiency were able to recover from COVID-19<sup>16, 17</sup>, suggesting a potential 94 role of cellular responses in fighting against SARS-CoV-2 infection. Induction 95 of CD8<sup>+</sup> T cell responses was documented in both SARS-CoV-2 infection and 96 vaccination<sup>18, 19</sup>. On the other hand, rapid induction of CD4<sup>+</sup> T cells is 97 associated with coordinated humoral and cellular response to a SARS-CoV-2 98 mRNA vaccine<sup>20</sup>. SARS-CoV-2 specific circulating T follicular helper cells 99 (cTFH) cells, whose counterparts in lymph nodes reinforce B cells and humoral 100 responses<sup>21</sup>, correlated with neutralizing antibody levels in convalescent 101 COVID-19 patients<sup>22, 23</sup>. 102

103

104 Nevertheless, T cell responses induced by inactivated vaccines are much less

well characterized than humoral immunity. One previous study revealed that
 the inactivated vaccine could elicit T cells response after 2 doses of
 vaccination<sup>24</sup>, but the phenotype and sustainability of antigen-specific CD4<sup>+</sup>
 and CD8<sup>+</sup> T cells remained unclear yet.

109

In this study, we sought to investigate the sustainability of immune memory 110 stimulated by the inactivated vaccine and profile humoral and cellular 111 responses to a third dose among HCWs. Although NAbs declined substantially, 112 113 SARS-CoV-2-specific memory B, CD4<sup>+</sup>, and CD8<sup>+</sup> T cells persisted in the peripheral blood 5 months after the second vaccination, even in participants 114 who were seronegative after receiving 2 doses of the inactivated vaccines. The 115 116 third vaccination robustly recalled both humoral and cellular immune responses in all participants. 117

118

#### 119 Materials and methods

#### 120 Human subjects

In this study, we conducted a non-randomized trial and recruited participants
from a prospective cohort at the First Affiliated Hospital of Sun Yat-sen
University (FAH-SYSU) in Guangzhou, China. As we described previously<sup>11</sup>,
63 HCWs received the inactivated SARS-CoV-2 vaccine BBIBP-CorV
(BBIBP-CorV, Sinopharm, Beijing) in the morning (9 am – 11 am) or afternoon
(3 pm – 5 pm) on day (d) 0 and d28, respectively. Fifty of the 63 HCWs were

volunteered to receive a third booster shot of the inactivated vaccine 6 months 127 after the prime vaccination (d180). They were assigned to the morning or 128 afternoon group as to their previous vaccinating time accordingly. 129 Demographic characteristics of the HCWs were summarized in Supplementary 130 Table 1. Blood samples were collected on d180 before the booster dose and 131 d187, d194 and d208 after the booster dose. Convalescent patients who had 132 recovered from SARS-CoV-2 infection were recruited as the positive control 133 (Supplementary Table 2). All studies were approved by the Institutional Review 134 135 Board of FAH-SYSU and written consent was obtained from all participants. The prospective cohort and the trial were registered to Chinese Clinical Trial 136 Registry (ChiCTR2100042222 and ChiCTR2100048665). 137

138

#### 139 **Cell isolation**

Blood samples were collected into the heparinized tubes and processed right after sample collection. Peripheral blood mononuclear cells (PBMCs) were isolated using density-gradient centrifugation. Briefly, blood samples were diluted with PBS at 1:1 ratio and loaded on top of Lymphoprep<sup>™</sup> (StemCell) in the Falcon tubes. The falcon tubes were then centrifuged at 1500 rpm for 30 mins. The medium layer was collected and washed with PBS twice. PBMCs were cryopreserved in Bambanker (StemCell) immediately.

147

## 148 SARS-CoV-2 neutralizing antibodies measurement

149	A one-step competitive Chemiluminescent immunoassay was used to detect
150	the concentration of NAbs against SARS-CoV-2 in sera by iFlash 2019-nCoV
151	NAb kit (YHLO Biotech Co, Ltd) as previously reported <sup>25</sup> . In this assay,
152	receptor binding domain (RBD) of the SARS-CoV-2 was coated on magnetic
153	beads. Acridinium ester-labeled ACE2 was designed to compete with
154	SARS-CoV-2 NAbs in sera for the RBD. NAb titers were calculated by an
155	iFlash3000 Chemiluminescence Immunoassay Analyzer (YHLO Biotech Co,
156	Ltd). Neutralizing activity is determined in arbitrary units (AU) and the cut-off is
157	10 AU/ml.

158

# 159 Ex vivo ELISpot assay

IFNy ELISpot assays were performed as described previously<sup>26</sup>. Briefly, 100 µl 160 of the coating antibody (15 µg/ml, MabTech, #3420-3-250) was added to the 161 well of ELISpot plate (MabTech) and incubated overnight at 4°C. The peptide 162 163 pool of SARS-CoV-2 spike protein (MabTech, #3630-1) was added to 300,000 PBMCs per test at a final concentration of 2 µg/ml for 24 h. Unstimulated cells 164 were used as negative control while anti-CD3/CD28 dynabeads (Thermo 165 Fisher) stimulated cells were set as the positive control. Plates were incubated 166 with IFNy detection antibody (1µg/ml, MabTech, #3420-6-250), followed by 167 Avidin-HRP (1µg/ml, Vector, #A-2004-5) and visualized using the ACE 168 substrate. Antigen-specific T cell responses were quantified by subtracting the 169 number of spots in unstimulated cells from the peptide stimulated cells. 170

171

SARS-CoV-2-specific B cell ELISpot was performed as previously described<sup>27</sup>. 172 173 Briefly, ELISpot plates were coated with 10 ug/ml recombinant RBD protein (Sino Biological, #40592-VNAH-100) and 8 ug/ml spike protein (Sino 174 175 Biological, #40589-V08B1) overnight at 4°C. To optimize the human IgG B cell ELISpot assay, PBMCs were cultured with a mixture of R848 (1 µg/ml, Tocris, 176 #4536/10) and IL-2 (20 ng/ml, PeproTech, #200-02-10) for 3 days to secrete a 177 detectable amount of antibody<sup>28, 29</sup>. After pre-stimulation, cells were washed 178 179 extensively to remove secreted antibodies. 500,000 PBMCs were added to the coated plates and incubated for 18 h at 37°C with 5% CO<sub>2</sub>. The following day, 180 cells were removed and plates were incubated with Biotin-anti-Human IgG 181 182 (1µg/ml, Jackson ImmunoResearch, #709-065-098). Plates were then incubated with Avidin-HRP followed by visualization with ACE substrate. 183 ELISpot plates were analyzed using an ELISpot counter (Cellular 184 185 Technologies Ltd). Results were expressed as spot-forming units (s.f.u.) per 10<sup>6</sup> PBMCs. Responses were considered positive if the results were at least 186 three times the mean of the negative control wells and >25 s.f.u. per  $10^6$ 187 PBMCs. Data were excluded when negative control wells had >30 s.f.u. per 188 189 10<sup>6</sup> PBMCs or positive control wells (anti-CD3/CD28 dynabeads) had no spot. 190

# 191 Activation-induced markers (AIM) T cell assay.

192 PBMCs were cultured in RPMI 1640 supplemented with 10% FBS and 1%

penicillin and streptomycin (Thermo Fisher) at 37 °C overnight. The cells were 193 then cultured with or without the peptide pool of SARS-CoV-2 spike protein (2 194 µg/ml) for 12 h. An equal concentration of DMSO in PBS was used as the 195 negative control. Antigen-specific T cells were measured as a percentage of 196 AIM<sup>+</sup> (OX40<sup>+</sup>CD137<sup>+</sup>) for CD4<sup>+</sup> T or (CD69<sup>+</sup>CD137<sup>+</sup>) for CD8<sup>+</sup> T cells after 197 stimulation of PBMCs with the peptide pool of spike protein<sup>26</sup>. After the 198 stimulation, cells were first stained with Zombie Red for dead cell exclusion. 199 Cells were then stained with anti-CD3-Pacific blue, anti-CD4-BV510, 200 201 anti-CD8-Percp, anti-CD69-Super Bright 436, anti-CD134 (OX40)-BV605 and anti-CD137-(4-1BB)-PE antibodies for antigen-specific T cell analysis. As for 202 phenotype analysis of SARS-CoV-2-specific T cells, cells were further labeled 203 204 with anti-CCR7-APC/cy7, anti-CD45RA-BV650, anti-CXCR5-BV711 and anti-PD-1-PE/cy7 antibodies. All FACS antibodies were from Biolegend. 205 Stimulation with anti-CD3/CD28 dynabeads was included as positive controls. 206 207 Any sample with a low response to anti-CD3/CD28 stimulation was excluded as quality control for the samples. Data were acquired by flow cytometry. 208

209

# 210 Detection of SARS-CoV-2-specific memory B cells

211 SARS-CoV-2-specific memory B cells were detected as we described 212 previously<sup>11</sup>. First, biotinylated antigens were multimerized with 213 fluorescence-labeled streptavidin individually. Recombinant spike protein 214 (R&D, #BT10549-050) was mixed with BV510-streptavidin (BioLegend) at 10:1

ratio and BV785-streptavidin (BioLegend) at 18:1 ratio at 4°C for 1h. 215 (R&D, Recombinant RBD protein #BT10500-050) mixed 216 was with BV421-streptavidin (BioLegend) at 20:1 ratio at 4°C for 1h. The antigen probes 217 prepared above were then mixed in 50mM free d-biotin (Macklin) in PBS to 218 ensure minimal cross-reactivity. PBMCs were thawed and let to rest at 37°C 219 with 5% CO2 for 2h and stained with Zombie Red (BioLegend) in PBS at room 220 temperature for 20 min. Cells were then stained with 50 µl of antigen probe 221 cocktail containing 100 ng of spike and 50 ng of RBD at 4°C for 30 min. Cells 222 223 were washed with PBS and then stained with the following antibody cocktail: anti-CD3-Pacific Blue<sup>™</sup>, anti-CD19-PE-CY7, anti-CD27-AF700, anti-IgD-FITC, 224 anti-CD38-BV650, anti-IgM-BV605, anti-IgG-AF647, anti-IgA-PE all from 225 226 BioLegend at 1:100 dilution. Samples were acquired by flow cytometry.

227

## 228 Detection of SARS-CoV-2-specific IFNy-producing T cells

229 The detection of spike-reactive T cells was performed as described with modification<sup>30</sup>. Briefly, overnight-rested PBMCs were cultured with or without 230 the peptide pool of SARS-CoV-2 spike protein (4 µg/ml) in the presence of 3 231 µg/ml of anti-CD28 monoclonal antibodies for 24 h. Cells were then incubated 232 with Brefeldin A for additional 5 h. Cells were stained with anti-CD3-Pacific 233 blue, anti-CD4-BV510, anti-CD8-Percp antibodies for surface markers. Cells 234 fixed with Cytofix/Cytoperm and 235 were then washed, stained with anti-IFNy-PE-Cy7 (BioLegend). Dead cells were excluded by Zombie Red 236

- staining. Samples were analyzed by flow cytometry. Samples without peptide
- stimulation were used as the negative control.
- 239

# 240 Flow cytometry

All flow cytometry samples were analyzed using cryopreserved cells which
were thawed and suspended in RPMI 1640 media supplemented with 2% FBS.
All samples were analyzed by flow cytometry with Cytek<sup>™</sup> AURORA. FlowJo
(Tree Star, USA) software was used for FACS data analysis. Details of
antibodies used in this study are listed in Supplementary Table 3.

246

# 247 ELISA-based antibody-antigen distribution analysis

248 All SARS-CoV-2 proteins were purchased from Sino Biological (Beijing, China). 200ng/well of SARS-CoV-2 spike (40589-V08B1), spike S1 subunit 249 (40591-V08H), spike NTD (40591-V49H), spike S2 subunit (40590-V08B), 250 251 RBD (40592-V08H), RBD T478K (40592-V08H91), nucleocapsid (40588-V08B) and envelope (40609-V10E3) were coated on the 96-well 252 ELISA plate overnight at 4 °C, respectively. Plates were washed by PBS 253 supplemented with 0.05% Tween-20 (PBST) three times, followed by blocking 254 255 with 5% BSA in PBST for 1 h at room temperature. Sera were diluted 20-fold for the first well and 4-fold serial diluted for subsequent wells in 5% BSA in 256 PBST, and incubated at 4°C overnight. Plates were washed 3 times by PBST, 257 and added with HRP-conjugated goat anti-human IgG antibody (2040-05, 258

SouthernBiotech, 1:3000) for 30 min at room temperature. Plates were
washed five times with PBST. 3,3',5,5'-Tetramethylbenzidine (TMB) substrate
(P0209, Beyotime) was added for 15 min, and stopped by the stopping buffer
(C1058, Solarbio). OD450 was measured by Varioskan Lux Microplate Reader
(Thermo Fisher).

264

# 265 **Pseudovirus neutralizing assay**

For the generation of SARS-CoV-2-Spike (Wuhan-Hu-1) pseudovirus <sup>31</sup>, 266 pcDNA3.1-2019-nCoV-Spike and pNL4-3 R<sup>-</sup>E<sup>-</sup> (gifts from Dr. Lu Lu, Fudan 267 University) were co-transfected to HEK293T with Lipo8000 (C0533, Beyotime) 268 according to the manufacturer's instruction. For the generation of the 269 270 B.1.617.2 Delta-variant spike pseudovirus, pCMV3-SARS-CoV-2-Spike (VG40804-UT, Sino Biological), pSPAX2 and pLenti-CMV-Luc-puro were 271 HEK293T. The 272 co-transfected to virus was harvested 72 hours post-transfection and stored at -80°C until use. 2x10<sup>4</sup> hACE2-293T/well were 273 seeded on the black flat-bottom 96-well plate (655090, Greiner Bio-one) for 16 274 hours in advance. Sera were diluted 10-fold for the first well and 4-fold serial 275 diluted for subsequent wells in DMEM, then co-incubated with pseudovirus at 276 277 37°C for 1 hour. Then the co-incubated samples, together with samples without sera or pseudovirus as controls, were subjected with 10µg/ml 278 polybrene (C0351, Beyotime) to the hACE2-293T for 6-hour absorption, 279 following by replacement of the culture medium for the next 42 hours 280

281	incubation at 37°C, 5% $CO_2$ . Infected cells were processed to the luciferase
282	assay using the Luciferase Assay System (E4550, Promega). The
283	illuminescence was measured by Varioskan Lux Microplate Reader (Thermo
284	Fisher). The 50% pseudovirus neutralization titer (pNT50) were determined by
285	four-parameter nonlinear regression curve (GraphPad Prism).

286

## 287 Statistical analysis

288 Statistical analysis was performed using Prism 5.0. Comparisons were 289 assessed using Wilcoxon rank sum test, Student's t-test, paired Student's t-test 290 or One-way ANOVA followed by Bonferroni's multiple comparison post-test as 291 appropriate. P values < 0.05 were considered as statistically significant.

292

293 **Results** 

294 Neutralizing antibody response is enhanced by a third dose of 295 inactivated SARS-CoV-2 vaccine BBIBP-CorV.

We have previously conducted a non-randomized trial and recruited HCWs from a prospective cohort, demonstrating the impact of the circadian rhythm on the immune response induced by a primary 2-dose series of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV, Sinopharm, Beijing)<sup>11</sup>. Fifty HCWs from this cohort were volunteered to participate in the current non-randomized trial to investigate the duration of the primary vaccination regimen and potential benefits of a third dose, given 5 months after the second dose (Fig. 1A). No

303 severe side effects related to vaccination were recorded during the trial
 304 (Supplementary Table 1).

305

Blood samples were collected from multiple time points before and after each dose and NAbs targeting RBD were measured by Chemiluminescent immunoassay<sup>25</sup>. The mean serum concentration of NAbs dropped by 70% from d56 (1 month post the second dose) to d180, 5 months after the second dose (Fig. 1B). Intriguingly, NAbs maintained a significantly higher level in the morning vaccination group than that in the afternoon group on d180 (Fig. 1D).

312

Although serum NAbs in 72% of participates (36/50) dropped below the 313 314 threshold (10 AU/ml) on d180, serological responses could be rapidly recalled to an unprecedented level within 1 week after the third dose. The mean 315 concentration of NAbs was increased by 7.2 folds from 8.8 AU/ml on d180 to 316 63.6 AU/ml on d187, peaking at 92.3 AU/ml 2 weeks after the booster (Fig. 1C). 317 As the primary vaccination series<sup>11</sup>, the circadian rhythm also governed the 318 outcome of the third dose, albeit only at the early stage. Significantly higher 319 levels of NAbs were observed in the morning group after the third dose on 320 321 d187 (Fig. 1D). However, the difference between the morning and the afternoon groups gradually diminished over time (Fig. 1D). Moreover, we did 322 323 not observe any difference in NAbs levels between females and males (Fig. 1E). 324

325

Pseudovirus neutralizing assays were next applied to confirm the elevation of 326 serum NAbs against wild type (WT) SARS-CoV-2 and VOCs by the third dose. 327 Consistent with the results of Chemiluminescent immunoassay, the 50% 328 pseudovirus neutralization titer (pNT50) against WT was greatly boosted (Fig. 329 1F). Encouragingly, the third dose not only elevated the NAbs against WT, but 330 also strengthen a cross-protective immune response. The mean serum pNT50 331 against B.1.167.2 Delta variant was increased by 10-fold from day180 to 332 333 day194 (Fig. 1G). In pseudovirus assay, a significantly higher level of NAbs against both WT and B.1.167.2 could still be observed in morning vaccination 334 participants (Fig. 1H and I). 335

336

One potential advantage of inactivated vaccines over other vaccine types is 337 that they comprise all viral structural proteins which may induce a broader 338 339 spectrum of immunity in addition to NAbs against RBD. To profile the antibody spectrum induced by BBIBP-CorV, serum IgG against major SARS-CoV-2 340 structural proteins and their subdomains, including S1, S2, RBD, NTD of spike 341 protein, nucleocapsid, and small envelope protein, were measured by indirect 342 ELISA before and after the third dose. As expected, BBIBP-CorV successfully 343 elicited antibodies against all structural proteins and subdomains tested 344 (Supplementary Fig. 1). Notably, we found all vaccinees were equipped with a 345 high titer of anti-envelope IgG which has not been reported in a vaccine study 346

elsewhere and was hardly induced even during natural SARS-CoV-2 infection<sup>32</sup>. Interestingly, the third dose did not elevate antibody responses against all tested structural proteins or subdomains evenly, but profoundly augment the immune response against the S1 domain of spike protein which comprises NTD and RBD subdomains (Supplementary Fig. 1).

352

#### 353 SARS-CoV-2 specific memory B cell response is robustly induced by a

#### 354 third dose of inactivated vaccine

The rapid and robust recall of humoral immune responses by the third vaccination indicated that the primary 2-dose vaccination regimen has established a sustained immune memory. We explored the presence of antigen-specific memory B cells before and after the third dose by flow cytometry.

360

Total B cell populations were first characterized by flow cytometry (Supplementary Fig. 2). Only mild changes in IgD<sup>+</sup>, IgM<sup>+</sup>, IgA<sup>+</sup> or IgD<sup>-</sup>CD27<sup>-</sup>B cells were found before and after the booster, whereas the percentage of total and naïve B cells were not affected (Supplementary Fig. 3), consistent with a good safety profile of the third dose (Supplementary Table. 1).

366

367 Next, antigen-specific B cell populations were investigated. Spike- and 368 RBD-specific memory B cells could be detected at 4 weeks (d56) and 5

months (d180) after the second dose, revealing that memory B cells persisted 369 despite a decreasing trend over a 5-months time frame between second and 370 371 third immunization (Fig. 2A and C). The third dose increased the percentages of spike- and RBD-specific memory B cells by 1.7 and 2.0 folds respectively 372 373 from d180 to d187, resulting in a significantly larger memory pool on d187 than that on d56 (Fig. 2B and D). The majority of these antigen-specific memory B 374 cells could be classified into IgG<sup>+</sup> or IgM<sup>+</sup> B cells, while a minor population of 375 them was IgA<sup>+</sup> B cells (Fig. 2E and F). 376

377

The capability of these Spike- or RBD-specific memory B cells in secreting 378 antibodies upon the antigen stimulation was further confirmed by B cell 379 380 ELISpot. The third dose boosted spike- or RBD-responsive, IgG-secreting B cells from 8 u.f.c/10<sup>6</sup> PBMCs to 17 u.f.c/10<sup>6</sup> PBMCs or 4 u.f.c/10<sup>6</sup> PBMCs to 381 10.7 u.f.c/10<sup>6</sup> PBMCs respectively (Fig. 2G-I). These results demonstrated that 382 the primary 2-dose vaccination regimen had equipped vaccinees with 383 long-lasting memory B cells which could be immediately recalled and further 384 expanded by a third dose of the inactivated vaccine. 385

386

387 The cellular immune response is boosted by a third dose of inactivated
 388 SARS-CoV-2 vaccine

389 Besides humoral immune responses, the cellular arm of immunity confers 390 another layer of protection, which may particularly crucial when B cell epitopes

mutate rapidly and continuously. Therefore, antigen-specific T cells induced by 391 the primary vaccination regimen and the third dose booster were next 392 393 investigated. Blood samples collected on d180 and d187 were stimulated by the spike peptide pool and IFNy-secreting cells were quantified by ELISpot. 394 Surprisingly, antigen-responsive IFNy-secreting T cells were readily detected 395 in all vaccinees even 5 months after the second dose, though a lower amount 396 was found in some participants (Fig. 3A and B). As IgG-secreting B cells, 397 IFNy-secreting T cell responses were also enhanced by 2.3 folds after the third 398 399 dose (Fig. 3A and B).

400

Next, SARS-CoV-2-specific CD8<sup>+</sup> were identified by AIM T cell assay, based 401 402 on the previous observation that antigen-specific CD8<sup>+</sup> T cells could be identified by CD69<sup>+</sup>4-1BB<sup>+</sup> after the peptide pool stimulation<sup>26</sup>. In line with 403 ELISpot, CD8+CD69+4-1BB+T cells were seen on d180, and further elevated 404 405 by 2.7 folds following a booster shot (Fig. 3C and D). Subsequent analysis on phenotypic markers revealed that the majority of the SARS-CoV-2-specific 406 CD8<sup>+</sup> T cells were CD45RA<sup>+</sup>CCR7<sup>-</sup> terminally differentiated effector memory 407 cells (T<sub>EMRA</sub>), whereas CD45RA<sup>-</sup>CCR7<sup>-</sup> effector memory T cells (T<sub>EM</sub>) 408 accounted for only one-fourth of the total antigen-specific CD8<sup>+</sup> T cells (Fig. 409 3E), similar to that from recovered COVID-19 patients<sup>26</sup>. The subsets of total 410 CD8<sup>+</sup> T cells were not affected (Supplementary Fig. 4 and Fig. 5). The 411 presence of antigen-specific CD8<sup>+</sup> T cells was further confirmed by 412

conventional intracellular cytokine staining (ICS) assay, in which PBMCs were
stimulated with spike peptide pool and IFNγ expression in CD8<sup>+</sup> T cells was
measured by flow cytometry. CD8<sup>+</sup> IFNγ<sup>+</sup> T cells were detected on d56, and
decreased over time till the third vaccination, which elevated IFNγ-expressing
CD8<sup>+</sup> T cells to a greater extent when compared to that on d56 (Fig. 3H and I).

418

SARS-CoV-2-specific CD4<sup>+</sup> T cells were identified by activation markers OX40 419 and 4-1BB after the peptide stimulation<sup>26</sup>. CD4+OX40+4-1BB+ T cells were 420 421 detected at a low level on d180. The third dose induced the expansion of these CD4<sup>+</sup> T cells by 5.9 folds within 1 week (Fig. 4A and B). Phenotypic analysis 422 showed that the majority of the SARS-CoV-2-specific CD4<sup>+</sup> T cells were 423 424 CD45RA<sup>-</sup>CCR7<sup>+</sup> T<sub>CM</sub> and CD45RA<sup>-</sup>CCR7<sup>-</sup> T<sub>EM</sub>, different from that of SARS-CoV-2-specific CD8<sup>+</sup> T cells (Fig. 4C). Among SARS-CoV-2-specific 425 CD4<sup>+</sup> T cells, 57.7% of the cells were CXCR5<sup>+</sup> cTFH cells (Fig. 4D-G). Among 426 427 total CD4<sup>+</sup> T cells, we observed the slightly decreased  $T_N$  cells, with increased T<sub>EM</sub> and T<sub>CM</sub> cells in the peripheral blood (Supplementary Fig. 4 and Fig. 5). 428 Again, SARS-CoV-2-specific CD4<sup>+</sup> T cells were confirmed by ICS assay. 429 CD4<sup>+</sup> IFNy<sup>+</sup> T cells showed a similar trend as that of CD8<sup>+</sup> IFNy<sup>+</sup> T cells. As 430 expected, the drop of antigen-specific CD4<sup>+</sup> T cells was reversed by the third 431 dose (Fig. 4H and I). 432

433

434 Besides CD4<sup>+</sup> and CD8<sup>+</sup> T cells, we also found a unique population,

SARS-CoV-2-specific CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>-</sup> T cells persisted 5 months after the
second immunization with inactivated vaccines, which were further elevated by
the third vaccination (Fig. 3F and G).

438

# A third dose of inactivated SARS-CoV-2 vaccine boosts immune responses in individuals with negative serologic responses to 2 doses.

The weakened or negative serological response has been noted in a small 441 group of vaccinees who had no known immunodeficiency disease or were not 442 443 in an immune-compromised condition. It is unclear that whether these people are true "non-responders", and whether a third dose is necessary and 444 beneficial as in immune-compromised patients<sup>33, 34</sup>. In this study, we found 445 446 NAbs were below the threshold in 9 participants after the primary 2-dose regimen. Of note, these participants have no known immunodeficiency disease 447 or are not in an immune-compromised condition. The level of NAbs in all of the 448 9 participants increased rapidly within 1 week and reach the peak 2 weeks 449 after the booster shot (Fig. 5A), though NAbs levels in these 9 participants 450 were still significantly lower than others who were seropositive after the second 451 dose (Fig. 5B). 452

453

The rapid recall of humoral responses indicated that the immune memory had been successfully established in these seronegative people after the second dose and persisted for at least 5 months. As expected, SARS-CoV-2-specific

memory B cells were indeed detected by labeling antigen-binding BCR in 457 these individuals on d56 and d180. The percentage of SARS-CoV-2-specific 458 memory B cells was guite stable over time between d56 and d180, and 459 increased significantly after the third dose (Fig. 5C). ELISpot was next enrolled 460 to identify functional memory B and T cells. Although no NAbs were detected 461 at any time point before the third dose, spike- or RBD-specific IgG-secreting 462 memory B cells were able to be detected by ELISpot on d56 and maintained at 463 a similar level till d180. The number increased within 1 week after the third 464 dose and persisted thereafter (Fig. 5D and F). 465

466

Spike-specific T cells were also able to be detected on d56 and d180 as 467 468 measured by ELISpot, albeit with a downward trend (Fig. 5G and H). As expected, the third dose was capable of enhancing T cell responses in this 469 population (Fig. 5H). The enhancement on SARS-CoV-2-specific CD4<sup>+</sup> and 470 471 CD8<sup>+</sup> T cells by the third dose was further confirmed by measuring AIM<sup>+</sup> T cells (OX40<sup>+</sup>4-1BB<sup>+</sup> for CD4<sup>+</sup> T cells and CD69<sup>+</sup>4-1BB<sup>+</sup> for CD8<sup>+</sup> T cells) by flow 472 cytometry. Both spike-specific CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells were successfully 473 expanded (Fig. 51 and J). We also observed the expansion of 474 SARS-CoV-2-specific cTFH cells in these participants (Fig. 5K). Taken 475 together, these results suggested that these participants were not true "no 476 responders", immune memory had been established but repeated antigen 477 stimulations were needed. 478

479

# 480 **Discussion**

In this study, we investigated the duration of B cell and T cell immunity 481 following the primary 2-dose vaccination regimen of the inactivated 482 SARS-CoV-2 vaccine BBIBP-CorV and the potential benefit of a third dose in a 483 non-randomized trial. Data in this study showed that neutralizing antibodies 484 gradually decreased after the second dose during a 5-month observation. 485 SARS-CoV-2-specific B cells and T cells were detected and persisted in the 486 peripheral blood 5 months after the second vaccination. Both humoral and 487 cellular responses were rapidly and robustly elevated by a third dose of 488 inactivated SARS-CoV-2 vaccine. The induction of both SARS-CoV-2-specific 489 490 memory B cells and T cells by the inactivated vaccine supports durable protection, as has been shown in mRNA vaccines and other settings<sup>35, 36</sup>. 491 Another key observation in this study was the successful induction of 492 493 antigen-specific memory B cell and T cell response in HCWs with low serological response to 2 doses of inactivation vaccines. 494

495

The NAb titers have been noted to decay following vaccination or SARS-CoV-2 infection<sup>37-39</sup>. However, HCWs who have recovered from COVID-19 show a substantially lower risk of reinfection with SARS-CoV-2<sup>40</sup>. The number of RBD-specific memory B cells remained relatively stable between 6 and 12 months after SARS-CoV-2 infection and BCR repertoire expanded markedly in

these recovered patients after receiving an mRNA vaccine<sup>41</sup>. Consistently, we 501 found that spike- and RBD-specific memory B cells could still be detected in all 502 503 COVID-19 convalescent patients up to 13 months after infection (Supplementary Fig. 6). SARS-CoV-2 mRNA vaccines were also capable of 504 inducing sustained immune memory and long-term protecting effects<sup>35, 42, 43</sup>. 505 Our study, together with these aforementioned studies, suggests that 506 SARS-CoV-2-specific memory B cells may sustain longer than plasma cells. 507 Prediction of vaccine efficacy should not solely rely on NAbs titers. Rather, 508 509 memory B cells should be taken into account whenever it is possible.

510

Recently, a third dose of inactivated vaccine CoronaVac elicited a rapid and 511 512 long-lasting recall antibody response with the capability of neutralizing several VOCs<sup>44</sup>. The rapid and strong secondary response by the inactivated vaccine 513 represents a characteristic secondary immune response, which demonstrates 514 515 the establishment of long-term immune memory within these participants. Our data confirm that SARS-CoV-2-specific memory B cells persisted 6 months 516 later the primary vaccination and expanded substantially by a third dose of 517 vaccine. The secondary immune response is one of the most important 518 features of immune memory stimulated by vaccination, which is characterized 519 by a faster and stronger immune response by memory B cells or plasma cells<sup>45</sup>. 520 Despite the waning of antibodies, the generation of SARS-CoV-2-specific 521 memory B cells could mediate recall response in future infection and provide 522

523 protective immunity. As has been observed in recovered COVID-19 patients, 524 long-lived bone marrow spike-binding plasma cells are quiescent<sup>27</sup>, which 525 explains the declining antibodies over time. Nonetheless, further investigation 526 should be conducted on how waning immunity could affect protection against 527 COVID-19.

528

Our data revealed that long-lasting memory B cells formed a basis for an 529 enormous lift of serum NAbs after the third dose, not only against WT 530 SARS-CoV-2 but also against B.1.617.2 Delta variant. As shown in 531 Supplementary Fig.1, the inactivated vaccine induced a broad spectrum of 532 antibody responses to multiple structural proteins of the virus. Whether the 533 534 lifted cross-reactive NAbs still targeted to RBD, or other domains of S protein, or even other proteins were involved, is an interesting question meriting further 535 study. 536

537

Our study showed that SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells in 538 convalescent COVID-19 patients could persist up to 13 539 months (Supplementary Fig. 7). SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells induced 540 by BBIBP-CorV were detected in all the HCWs who received 2 doses of 541 vaccine and last for at least 5 months. In line with previous data from an mRNA 542 vaccine<sup>20</sup>, SARS-CoV-2-specific CD4<sup>+</sup> T cells induced by inactivated vaccine 543 mainly fall into central and effector memory subsets, while the majority of 544

SARS-CoV-2-specific CD8<sup>+</sup> T cells were T<sub>EMRA</sub> cells. Because of the high 545 CCR7 expression, the central memory T cells reside in the secondary 546 lymphoid organs and readily expand upon infection or booster vaccination. 547 Effector memory T cells circulate in between blood and peripheral tissues, 548 providing prompt immune response at the early time point of infection<sup>46, 47</sup>. For 549 the emergence of VOCs of SARS-CoV-2, there is growing concern over 550 vaccine efficacy. In addition, T cells from COVID-19 convalescents and in 551 recipients of mRNA vaccine could recognize epitopes throughout the 552 553 SARS-CoV-2 spike protein and the total reactivity against SARS-CoV-2 variants of B.1.1.7, B.1.351, P.1, and CAL.20C lineages were mostly 554 maintained in terms of magnitude and frequency response<sup>48</sup>. 555 of 556 SARS-CoV-2-specific T cells from convalescent COVID-19 patients or vaccinated individuals targeted the conserved epitopes between prototype and 557 VOCs<sup>49, 50</sup>. Thus, SARS-CoV-2-specific T cells are less likely to be affected by 558 559 antibody escapes mutations in VOCs. Moreover, the inactivated virus vaccine comprises all viral structural proteins. This means more epitopes, especially 560 those conserved epitopes in proteins other than spike are engaged as 561 compared to mRNA or recombinant protein vaccines involving only RBD or 562 spike. Ideally, a potent adjuvant rather than aluminum salts should be used to 563 fully realize this advantage. 564

565

566 Another interesting finding of this study was the induction of

SARS-CoV-2-specific cTFH cells by the inactivated vaccine. Our previous 567 study has demonstrated the mobilization of cTFH cells after the first dose of 568 inactivated vaccination<sup>11</sup>. For the relatively late development of humoral 569 response by the inactivated vaccines, early response of cTFH cells could 570 contribute to the early protection of vaccination when antibody level was still 571 low<sup>3, 51</sup>. cTFH cells have been associated with humoral response in COVID-19 572 patients or vaccination individuals<sup>20, 23</sup>. Data in this study further confirmed that 573 the induction of cTFH cells by the inactivated vaccine correlated with humoral 574 575 response closely.

576

A third dose of the SARS-CoV-2 vaccine may be particularly in need for the 577 578 immunocompromised population. Low seroconversion rates to mRNA vaccination have been reported in solid transplant recipients<sup>52</sup>. The 579 applications of immune suppressants or B cell-targeted therapies could also 580 hamper serological response to vaccination<sup>53, 54</sup>. Recently, data show that 581 antibody response was enhanced in kidney transplant recipients with minimal 582 serologic response to 2 doses by a third dose of mRNA vaccine<sup>33</sup>. In this study, 583 we found that a group of healthy individuals was not mounted with detectable 584 NAbs by two doses of vaccination. However, memory B and T cells could be 585 detected 5 months after the second immunization. The third dose of 586 inactivated vaccine could induce an elevated level of NAbs and an extensive 587 expansion of memory cells within 1 week, suggesting that the memory 588

response could also be effectively recalled upon SARS CoV-2 infection. Therefore, these individuals were not true "non-responders" but already equipped with immune memory which may at least confer protection against severe diseases. Nevertheless, it should be noted that further studies are needed to confirm the relevance between these memory responses and protection. Moreover, a third dose is necessary to further secure the protection.

595

In conclusion, our study revealed sustained memory B and T cell responses after a standard 2-dose vaccination regimen of inactivated vaccines. Immune responses against SARS-CoV-2 were readily recalled and further elevated by a third dose of the inactivated vaccine, which is especially beneficial for individuals facing high exposure risks, such as HCWs, and has been demonstrated to be safe and effective in our study and others<sup>33, 55</sup>.

602

# 603 Author Contributions:

HX, HZ and JW supervised the study. YL, QZeng, CD, MLi, LL and DL
contributed equally to the study. HX, HZ, JW and YL conceived and designed
the study. YL, DL, JM and RM recruited participants in the trial and collected
blood samples. QZeng, CD, ML, MLi and LL performed the experiments and
collected data. QZeng and QZhou performed statistical analysis. HZ, YL,
QZeng, CD, MLi, LL and DL drafted the report. HX, JW, SP and MLiu made
critical revision on the manuscript. All authors contributed to the interpretation

of data. All authors approved the final version before submission.

612

# 613 Acknowledgment

- 614 We thank Prof. Lu Lu at Fudan University for his kind help in pseudovirus
- assays. The work is supported by The Talent Program of the First Affiliated
- Hospital, Sun Yat-sen University (Y70311) and The Hundred Talent Program of
- 617 Sun Yat-sen Univetsity (Y61229).

618

619 **Conflict interests**: The authors have no conflicts of interest to disclose.

620

# 622 **Reference**:

- 1 Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms,
- risk factors, and management. *BMJ* 2021; **374**:n1648.
- 625 2 COVID-19 Map Johns Hopkins Coronavirus Resource Center.
- 626 <u>https://coronavirusjhuedu/maphtml</u> 2021.
- 3 Xia S, Zhang Y, Wang Y et al. Safety and immunogenicity of an inactivated
- 628 SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind,
- placebo-controlled, phase 1/2 trial. *Lancet Infect Dis* 2021; **21**:39-51.
- 4 Jackson LA, Anderson EJ, Rouphael NG et al. An mRNA Vaccine against
- 631 SARS-CoV-2 Preliminary Report. *N Engl J Med* 2020; **383**:1920-1931.
- 5 Krause PR, Gruber MF. Emergency Use Authorization of Covid Vaccines -
- 633 Safety and Efficacy Follow-up Considerations. *N Engl J Med* 2020; **383**:e107.
- 634 6 Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are
- 635 highly predictive of immune protection from symptomatic SARS-CoV-2
- 636 infection. *Nat Med* 2021; **27**:1205-1211.
- 7 Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently
   needed. *Nat Med* 2021; 27:1147-1148.
- 639 8 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure,
- 640 Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020;
- 641 **181:281-292 e286**.
- 9 Goel RR, Apostolidis SA, Painter MM *et al.* Distinct antibody and memory B
   cell responses in SARS-CoV-2 naive and recovered individuals following

- 644 mRNA vaccination. *Sci Immunol* 2021; **6**.
- 10 Xia S, Duan K, Zhang Y et al. Effect of an Inactivated Vaccine Against
- 646 SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2
- 647 Randomized Clinical Trials. *JAMA* 2020; **324**:951-960.
- 11 Zhang H, Liu Y, Liu D *et al.* Time of day influences immune response to an
- 649 inactivated vaccine against SARS-CoV-2. *Cell Res* 2021.
- 12 Marot S, Malet I, Leducq V et al. Rapid decline of neutralizing antibodies
- against SARS-CoV-2 among infected healthcare workers. *Nat Commun* 2021;
- 652 **12:844**.
- 13 Shrotri M, Navaratnam AMD, Nguyen V et al. Spike-antibody waning after
- 654 second dose of BNT162b2 or ChAdOx1. *Lancet* 2021; **398**:385-387.
- 14 Krause PR, Fleming TR, Longini IM et al. SARS-CoV-2 Variants and
- 656 Vaccines. *N Engl J Med* 2021; **385**:179-186.
- 15 Pegu A, O'Connell S, Schmidt SD et al. Durability of mRNA-1273
- vaccine-induced antibodies against SARS-CoV-2 variants. *Science* 2021.
- 16 Soresina A, Moratto D, Chiarini M *et al.* Two X-linked agammaglobulinemia
- 660 patients develop pneumonia as COVID-19 manifestation but recover. Pediatr
- 661 Allergy Immunol 2020; **31**:565-569.
- 17 Wurm H, Attfield K, Iversen AK, Gold R, Fugger L, Haghikia A. Recovery
- 663 from COVID-19 in a B-cell-depleted multiple sclerosis patient. *Mult Scler* 2020;
- 664 **26**:1261-1264.
- 665 18 Oberhardt V, Luxenburger H, Kemming J et al. Rapid and stable

666 n	nobilization	of CD8(+	) T	cells by	SARS-CoV-2 mRNA vaccine	e. Nature 2021.
-------	--------------	----------	-----	----------	-------------------------	-----------------

- 19 Kared H, Redd AD, Bloch EM et al. SARS-CoV-2-specific CD8+ T cell
- responses in convalescent COVID-19 individuals. *J Clin Invest* 2021; **131**.
- 20 Painter MM, Mathew D, Goel RR et al. Rapid induction of antigen-specific
- 670 CD4(+) T cells is associated with coordinated humoral and cellular immunity to
- 671 SARS-CoV-2 mRNA vaccination. *Immunity* 2021.
- 21 Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;
- 673 **29:621-663**.
- 22 Boppana S, Qin K, Files JK et al. SARS-CoV-2-specific circulating T
- follicular helper cells correlate with neutralizing antibodies and increase during
  early convalescence. *PLoS Pathog* 2021; **17**:e1009761.
- 23 Juno JA, Tan HX, Lee WS et al. Humoral and circulating follicular helper T
- cell responses in recovered patients with COVID-19. *Nat Med* 2020;
  26:1428-1434.
- 680 24 Deng Y, Li Y, Yang R, Tan W. SARS-CoV-2-specific T cell immunity to
- 681 structural proteins in inactivated COVID-19 vaccine recipients. Cell Mol
- 682 *Immunol* **2021**; **18**:2040-2041.
- 25 Tenbusch M, Schumacher S, Vogel E *et al.* Heterologous prime-boost
  vaccination with ChAdOx1 nCoV-19 and BNT162b2. *Lancet Infect Dis* 2021;
  21:1212-1213.
- 26 Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2
- assessed for up to 8 months after infection. *Science* 2021; **371**.

688 27 Turner JS, Kim W, Kalaidina E et al. SARS-CoV-2 infection induces

- long-lived bone marrow plasma cells in humans. *Nature* 2021; **595**:421-425.
- 690 28 Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, Ahlborg N.
- 691 Optimization of a human IgG B-cell ELISpot assay for the analysis of
- vaccine-induced B-cell responses. *J Immunol Methods* 2013; **391**:50-59.
- 29 Long QX, Jia YJ, Wang X *et al.* Immune memory in convalescent patients
  with asymptomatic or mild COVID-19. *Cell Discov* 2021; **7**:18.
- 30 Peng Y, Mentzer AJ, Liu G et al. Broad and strong memory CD4(+) and
- 696 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals
- 697 following COVID-19. *Nat Immunol* 2020; **21**:1336-1345.
- 31 Xia S, Liu M, Wang C *et al.* Inhibition of SARS-CoV-2 (previously
  2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor
  targeting its spike protein that harbors a high capacity to mediate membrane
  fusion. *Cell Res* 2020; **30**:343-355.
- 702 32 Tea F, Ospina Stella A, Aggarwal A et al. SARS-CoV-2 neutralizing
- antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS
- 704 *Med* 2021; **18**:e1003656.
- 33 Benotmane I, Gautier G, Perrin P et al. Antibody Response After a Third
- 706 Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant 707 Recipients With Minimal Serologic Response to 2 Doses. *JAMA* 2021.
- 708 34 Hall VG, Ferreira VH, Ku T et al. Randomized Trial of a Third Dose of
- mRNA-1273 Vaccine in Transplant Recipients. *N Engl J Med* 2021.

710	35 Goel RR, Painter MM, Apostolidis SA et al. mRNA Vaccination Induces
711	Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants
712	of Concern. <i>bioRxiv</i> 2021.
713	36 Akondy RS, Fitch M, Edupuganti S et al. Origin and differentiation of human
714	memory CD8 T cells after vaccination. <i>Nature</i> 2017; <b>552</b> :362-367.
715	37 Israel A, Shenhar Y, Green I et al. Large-scale study of antibody titer decay
716	following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv 2021.
717	38 Long QX, Tang XJ, Shi QL et al. Clinical and immunological assessment of
718	asymptomatic SARS-CoV-2 infections. Nat Med 2020; 26:1200-1204.
719	39 Ibarrondo FJ, Fulcher JA, Goodman-Meza D et al. Rapid Decay of
720	Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. N Engl J Med
721	2020; <b>383</b> :1085-1087.
722	40 Hall VJ, Foulkes S, Charlett A et al. SARS-CoV-2 infection rates of
723	antibody-positive compared with antibody-negative health-care workers in
724	England: a large, multicentre, prospective cohort study (SIREN). Lancet 2021;
725	<b>397</b> :1459-1469.
726	41 Wang Z, Muecksch F, Schaefer-Babajew D et al. Naturally enhanced
727	neutralizing breadth against SARS-CoV-2 one year after infection. Nature
728	2021; <b>595</b> :426-431.
729	42 Doria-Rose N, Suthar MS, Makowski M et al. Antibody Persistence through
730	6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl
731	J Med 2021: <b>384</b> :2259-2261.

732	43 Tenforde MW, Self WH, Naioti EA et al. Sustained Effectiveness of
733	Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated
734	Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb
735	Mortal Wkly Rep 2021; <b>70</b> :1156-1162.
736	44 Kang W. ea. A third dose of inactivated vaccine 1 augments the potency,
737	breadth, and duration of anamnestic responses against SARS-CoV-2.
738	medRxiv 2021.
739	45 Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity
740	2021; <b>54</b> :205-210.
741	46 Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation:
742	implications for vaccine development. Nat Rev Immunol 2002; 2:251-262.
743	47 Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector
744	memory T cell subsets: function, generation, and maintenance. Annu Rev
745	Immunol 2004; <b>22</b> :745-763.
746	48 Tarke A, Sidney J, Methot N et al. Impact of SARS-CoV-2 variants on the
747	total CD4(+) and CD8(+) T cell reactivity in infected or vaccinated individuals.
748	<i>Cell Rep Med</i> 2021; <b>2</b> :100355.
749	49 Skelly DT, Harding AC, Gilbert-Jaramillo J et al. Two doses of SARS-CoV-2
750	vaccination induce robust immune responses to emerging SARS-CoV-2
751	variants of concern. Nat Commun 2021; <b>12</b> :5061.
752	50 Redd AD, Nardin A, Kared H et al. CD8+ T-Cell Responses in COVID-19

753 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent

754 SARS-CoV-2 Circulating Variants. Open Forum Infect Dis 2021; 8:ofab143.

- 755 51 Al Kaabi N, Zhang Y, Xia S et al. Effect of 2 Inactivated SARS-CoV-2
- 756 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized
- 757 Clinical Trial. JAMA 2021; **326**:35-45.
- 52 Boyarsky BJ, Werbel WA, Avery RK et al. Antibody Response to 2-Dose
- 759 SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients.
- 760 *JAMA* 2021; **325**:2204-2206.
- 761 53 Haberman RH, Herati R, Simon D et al. Methotrexate hampers
- <sup>762</sup> immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated
- <sup>763</sup> inflammatory disease. Ann Rheum Dis 2021.
- 764 54 Mrak D, Tobudic S, Koblischke M et al. SARS-CoV-2 vaccination in
- rituximab-treated patients: B cells promote humoral immune responses in the
- presence of T-cell-mediated immunity. Ann Rheum Dis 2021.
- 55 Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three
- 768 Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N
- 769 *Engl J Med* 2021; **385**:661-662.
- 770
- 771

#### **Figures and legends** 772



Figure 1 Humoral responses induced by a third dose of inactivated 774 SARS-CoV-2 vaccine BBIBP-CorV. (A) Protocol of the prospective cohort 775 and the non-randomized trial. Healthcare workers (HCWs) were recruited from 776 a perspective cohort who received two doses of an inactivated vaccine either 777 in the morning (AM, n=25) or afternoon (PM, n=25) on day (d) 0 and d28. They 778 were assigned to morning or afternoon vaccination to receive a third dose of 779 the inactivated vaccine on day 180 according to their previous vaccinating time. 780

781	Blood samples were collected on different time points d0 (T1), d14 (T2), d21
782	(T3), d28 (T4), d56 (T5), d180 (T6), d187 (T7), d194 (T8) and d208 (T9). (B-E)
783	Neutralizing antibodies (NAbs) against SARS-CoV-2 in the serum of each
784	volunteer was measured by Chemifluorescence Assay longitudinally. (B) The
785	concentration of NAbs in the sera at different time points was summarized and
786	shown in the box plot. (C) The longitudinal changes of NAbs in the sera before
787	and after the third dose of vaccination. (D) NAbs in the sera from the morning
788	or afternoon group at different time points. (E) NAbs concentrations in the sera
789	of female or male. Medians of the data were shown. (F, G) Neutralizing
790	activities of sera from T6 and T8 against SARS-CoV-2 wild type (WT) and
791	Delta variant (B.1.167.2) were measured by pseudovirus neutralizing assay. (H,
792	I) Comparison of neutralizing activities between the morning and afternoon
793	group on T8. Data are mean ± SEM. Comparisons were done by Wilcoxon
794	rank sum test in B, D, E or Student's t-test in F-I. **p<0.01, ****p<0.0001; ns,
795	not significant.

796



799 inactivated vaccine. Recombinant spike or receptor binding domain (RBD) 800 proteins were used to label SARS-CoV-2-specific BCRs. Data were acquired 801 by flow cytometry. (A, C) Representative FACS plots for spike- or RBD-specific 802 BCR were shown. (B, D) Longitudinal changes of spike- or RBD-specific 803

memory B cells were summarized. (E) IgG<sup>+</sup>, IgA<sup>+</sup> and IgM<sup>+</sup> B cells were 804 measured by flow cytometry. UMAP plot demonstrated the distribution of 805 spike- and RBD-specific memory B cells in IgG<sup>+</sup>, IgA<sup>+</sup> and IgM<sup>+</sup> B cells. (F) 806 Mean percentages of each BCR subtype in spike- and RBD-specific B cells 807 were summarized. (G) Spike- or RBD-specific IgG-secreting B cells were 808 measured by ELISpot after incubating PBMCs in spike- or RBD-coated plates 809 for 18 h. Representative ELISpot images were shown. (H, I) Numbers of Spike-810 or RBD-specific IgG-secreting B cells per 10<sup>6</sup> PBMCs were summarized. 811 812 Comparisons were done by one-way ANOVA corrected for multiple comparison in panels B, D and Student's paired-T test in panels H and I. 813 \*\*\*p<0.001, \*\*\*\*p<0.0001; ns, not significant. 814





Figure 3 Cellular responses induced by a third dose of inactivated 817 SARS-CoV-2 vaccine. (A) PBMCs were stimulated with or without the spike 818 peptide pool (2 µg/ml). Anti-CD3/CD28 dynabeads served as positive control. 819 IFNy producing T cells were detected by ELISpot after 24 h incubation. 820 Representative images of ELISpot wells were shown. (B) The number of 821 IFNy-producing T cells was quantified as the spot-forming units (s.f.u.) per 10<sup>6</sup> 822 PBMCs. (C-G) PBMCs were stimulated with spike peptide pool (2 µg/ml) for 12 823 h. Activation-induced markers (AIM) CD69 and 4-1BB were measured by flow 824 cytometry. (C) Representative FACS plots showing the SARS-CoV-2-specific 825

826	AIM <sup>+</sup> CD8 <sup>+</sup> T cells. (D) Percentages of AIM <sup>+</sup> CD8 <sup>+</sup> T cells were summarized. (E)
827	T <sub>N</sub> (CD45RA <sup>+</sup> CCR7 <sup>+</sup> ), T <sub>EM</sub> (CD45RA <sup>-</sup> CCR7 <sup>-</sup> ), T <sub>CM</sub> (CD45RA <sup>-</sup> CCR7 <sup>+</sup> ), T <sub>ERMA</sub>
828	(CD45RA <sup>+</sup> CCR7 <sup>-</sup> ) populations in AIM <sup>+</sup> CD8 <sup>+</sup> T cells. (F, G)
829	SARS-CoV-2-specific CD3+CD4-CD8- (DN) T cells were identified by CD69
830	and 4-1BB after spike peptide pool stimulation. (H, I) Intracellular cytokine
831	staining assays were performed to confirm the presence of
832	SARS-CoV-2-specific CD8 <sup>+</sup> T cells in PBMCs by measuring intracellular IFN $\gamma$
833	expression after peptide pool stimulation. Comparisons were done by
834	Student's paired-T test in panels B, D and G and one-way ANOVA corrected
835	for multiple comparison in panel I. ****p<0.0001; ns, not significant.





Figure 4 Rapid induction of CD4<sup>+</sup> T cells by the third dose. (A, B) 838 Activation-induced markers (AIM) OX40 and 4-1BB in CD4<sup>+</sup> T cells were 839 detected after incubating PBMCs with spike peptide pool (2 µg/ml) for 12 h. 840 Percentages of AIM<sup>+</sup> CD4<sup>+</sup> T cells in the PBMCs were summarized. (C) T<sub>N</sub> 841  $(CD45RA^+CCR7^+), T_{EM} (CD45RA^-CCR7^-),$ T<sub>CM</sub> (CD45RA<sup>-</sup>CCR7<sup>+</sup>), T<sub>ERMA</sub> 842 (CD45RA<sup>+</sup>CCR7<sup>-</sup>) populations in AIM<sup>+</sup> CD4<sup>+</sup> T cells were gated. (D) 843 Expression of CXCR5 in AIM<sup>+</sup> CD4<sup>+</sup> T cells was measured by flow cytometry. 844 (E) Percentages of circulating follicular helper T cells (cTFH) in total CD4<sup>+</sup> T 845

846	cells were summarized. (F) UMAP plot showed the distribution of cTFH cells
847	among AIM <sup>+</sup> CD4 <sup>+</sup> T cells. (G) Percentage of cTFH cells in AIM <sup>+</sup> CD4 <sup>+</sup> T cells.
848	(H, I) Intracellular cytokine staining assays were performed to confirm the
849	presence of SARS-CoV-2-specific CD4+ T cells in PBMCs by measuring
850	intracellular IFN $\gamma$ expression after peptide pool stimulation. Comparisons were
851	done by Student's paired-T test in panels B and E and one-way ANOVA
852	corrected for multiple comparison in panel I. *p<0.05, ***p<0.001,
853	****p<0.0001.



855

Figure 5 Immune responses in healthcare workers with minimal 856 serologic response to a standard two-dose vaccination schedule. (A) 857 Serum NAbs in HCWs with minimal serologic response to a standard two-dose 858 vaccination schedule were analyzed longitudinally at different time points 859 before and after the third dose (red arrow). (B) Comparison of NAbs between 860

vaccinees with negative or positive serological responses to a standard 861 two-dose vaccination schedule. (C) Percentages of spike-specific memory B 862 cells in HCWs with a negative serological response to a standard two-dose 863 vaccination schedule. (D-F) Numbers of spike- or RBD-specific IgG-producing 864 B cells in HCWs with a negative serological response to a standard two-dose 865 vaccination schedule. (G, H) Numbers of spike-specific IFNy producing T cells 866 as detected by ELISpot in HCWs with a negative serological response to a 867 standard two-dose vaccination schedule. (I-K) Spike-specific T cells, including 868 869 CD69+4-1BB+CD8+ Т cells. OX40+4-1BB+CD4+ Т cells and CXCR5<sup>+</sup>OX40<sup>+</sup>4-1BB<sup>+</sup> cTFH in HCWs with a negative serological response to 870 a standard two-dose vaccination schedule. Comparisons were done by 871 872 Wilcoxon rank sum test in B and One-way ANOVA corrected for multiple comparison in the rest panels. \*p<0.05, \*\*p<0.01, \*\*\*\*p<0.0001; ns, not 873 significant. 874